Welcome to our dedicated page for AngioDynamics news (Ticker: $ANGO), a resource for investors and traders seeking the latest updates and insights on AngioDynamics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AngioDynamics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AngioDynamics's position in the market.
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) will report financial results for Q2 of fiscal year 2024 on January 5, 2024. The management will host a conference call to discuss the results, accessible via phone or webcast. The webcast replay and call recording will also be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) has completed the patient enrollment in the APEX-AV study, evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for treating acute intermediate-risk pulmonary embolism (PE). The study enrolled 122 patients across 25 hospital-based sites in the US, with a focus on reducing thrombus burden and improving right ventricular function. The primary efficacy and safety endpoints of the study are the reduction in RV/LV ratio and the rate of Major Adverse Events (MAEs) within the first 48 hours post-procedure. The study aims to broaden the treatment options for PE, which affects around 900,000 people in the US every year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
-
Rhea-AI Summary
AngioDynamics, Inc. reports Q1 FY2024 financial results with net sales of $78.7 million, a 5.7% increase excluding Dialysis and BioSentry sales. Med Tech net sales increased 13.3% to $25.9 million. Gross margin declined 20 basis points to 50.9% on a pro-forma basis. Completed sale of Dialysis and BioSentry businesses for $100 million. Adjusted loss per share of $0.12. Cash and cash equivalents at $57.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
Rhea-AI Summary
AngioDynamics, Inc. will report Q1 FY2024 financial results on October 4, 2023, before market open. Conference call scheduled at 8:00 a.m. ET to discuss results. Webcast available on company website. Recording of call available until October 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
-
Rhea-AI Summary
AngioDynamics receives FDA Breakthrough Device designation for AngioVac System's non-surgical removal of vegetation from the right heart.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) to participate in fireside chat at Canaccord Genuity 43rd Annual Growth Conference. The company's President and CEO, Jim Clemmer, and CFO, Stephen Trowbridge, will discuss the latest developments in medical technology and cancer treatment options. The live webcast will be accessible through the 'Investors' section of the company's website at www.angiodynamics.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
Rhea-AI Summary
AngioDynamics, Inc. has announced the appointment of Lorinda Burgess to its Board of Directors. Ms. Burgess brings over 35 years of management and financial experience, including over 15 years at Medtronic, Inc. She has a track record of driving growth and profitability through transformative strategies. AngioDynamics aims to become a profitable, high-growth medical technology company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
AngioDynamics, Inc.
Nasdaq:ANGO
ANGO Rankings
ANGO Stock Data
248.34M
38.86M
5%
91.34%
5.65%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
LATHAM
About ANGO
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie